1 Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized

2 Controlled Trial of Ivabradine for Those With Postural Orthostatic Tachycardia

- **3** Syndrome (The COVIVA Study)
- 4 David Saunders¹[§]; Thomas B. Arnold^{1,2,4}; Jason M. Lavender^{1,2,4}; Daoqin Bi^{1,4,5}; Karl Alcover¹;
- 5 Lydia D. Hellwig^{1,3,5}; Sahar T Leazer^{1,2,4}; Roshila Mohammed^{1,2,4}; Bethelhem Markos^{1,2,4};
- 6 Kanchana Perera^{1,2,4}; Dutchabong Shaw^{1,5}; Priscilla Kobi^{1,5}; Martin Evans⁶; Autumn Mains^{1,2,4};
- 7 Marian Tanofsky-Kraff^{1,4}; Emilie Goguet^{1,5}; Edward Mitre¹; Kathleen P Pratt¹; Clifton L
- 8 Dalgard^{1,3,}; Mark C Haigney, MD^{1,4}

9 § - Corresponding Author

- 10 COL David Saunders, MD, MPH
- 11 Uniformed Services University
- 12 4301 Jones Bridge Road
- 13 Bethesda, MD 20814-4712
- 14 Office: (301) 318-6024
- 15 Email: david.saunders@usuhs.edu
- 16

17 Affiliations

- 18 1 Uniformed Services University School of Medicine, Bethesda, Maryland
- 19 2 The Metis Foundation, San Antonio, Texas
- 20 3 Center for Military Precision Health, Uniformed Services University, Bethesda, MD
- 21 4 Military Cardiovascular Outcomes Research, Uniformed Services University, Bethesda, MD
- 22 5 Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
- 23 6 Walter Reed Army Institute of Research, Silver Spring, MD
- 24
- 25

26 Abstract

27 **Background:** Significant clinical similarities have been observed between the recently described 'Long-Haul' COVID-19 (LHC) syndrome, Postural Orthostatic Tachycardia 28 29 Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST). Shared symptoms include lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, chest pain, 30 dyspnea, "brain-fog", and fatigue. Ivabradine is a selective sinoatrial node blocker FDA-31 32 approved for management of tachycardia associated with stable angina and heart failure not fully managed by beta blockers. In our study we aim to identify risk factors underlying LHC, as well 33 34 as the effectiveness of ivabradine in controlling heart rate dysregulations and POTS/IST related 35 symptoms.

Methods/Design: A detailed prospective phenotypic evaluation combined with multi-omic 36 37 analysis of 200 LHC volunteers will be conducted to identify risk factors for autonomic 38 dysfunction. A comparator group of 50 volunteers with documented COVID-19 but without LHC will be enrolled to better understand the risk factors for LHC and autonomic dysfunction. 39 Those in the cohort who meet diagnostic criteria for POTS or IST will be included in a nested 40 41 prospective, randomized, placebo-controlled trial to assess the impact of ivabradine on symptoms and heart rate, assessed non-invasively based on physiologic response and ambulatory 42 43 electrocardiogram. Additionally, studies on catecholamine production, mast cell and basophil 44 degranulation, inflammatory biomarkers, and indicators of metabolic dysfunction will be 45 measured to potentially provide molecular classification and mechanistic insights.

46 **Discussion:** Optimal therapies for dysautonomia, particularly associated with LHC, have yet to 47 be defined. In the present study, ivabradine, one of numerous proposed interventions, will be

48	systematically evaluated for therapeutic potential in LHC-associated POTS and IST.
49	Additionally, this study will further refine the characteristics of the LHC-associated POTS/IST
50	phenotype, genotype and transcriptional profile, including immunologic and multi-omic analysis
51	of persistent immune activation and dysregulation. The study will also explore and identify
52	potential endotheliopathy and abnormalities of the clotting cascade.
53	

54 **Trial registration:** ClinicalTrials.gov, ID:NCT05481177 Registered on 29 July 2022.

55

Keywords: Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-CoV-2 or COVID-19);
long-haul COVID-19 (LHC); postural orthostatic tachycardia syndrome (POTS); ivabradine

58 (Procoralan); clinical trial

59 Background

60 Introduction & Significance

Between 13-70% of coronavirus disease 2019 (COVID-19) survivors continue to experience 61 62 symptoms after >12 weeks of resolution of primary illness. This phenomenon has been termed "Long Haul COVID-19" (LHC). There is a plethora of reported LHC symptoms including 63 dizziness, tachycardia, palpitations, confusion, fatigue, memory loss, dyspnea and many more 64 65 (1).¹ LHC symptoms greatly degrade an individual's quality of life and functional ability. The 66 Postural Orthostatic Tachycardia Syndrome (POTS) sometimes referred to as Soldier's Heart or DaCosta's Syndrome is a particularly debilitating condition (2). POTS overlaps with several of 67 68 the clinical features of LHC, particularly tachycardia, confusion, and fatigue. Prior to COVID-69 19, POTS was a relatively rare phenomenon, affecting otherwise healthy individuals following 70 viral illness or trauma. Recent reports suggest that a substantial number of LHC patients meet 71 diagnostic criteria for POTS (3). Clinics dedicated to the treatment of autonomic disorders are 72 seeing substantially increased numbers of POTS patients among those who have recovered from 73 COVID-19. The American Autonomic Society issued a statement alerting clinicians to consider 74 the possibility of POTS when assessing LHC patients (4). However, the actual prevalence of 75 those with LHC also meeting the diagnostic criteria for POTS has been only minimally 76 characterized. Inappropriate Sinus Tachycardia (IST) is a related syndrome associated with sinus 77 heart rates that are elevated above 100 beats per minute at rest and an average rate >90 over a 24hour period. The symptoms associated with IST are similar to those of POTS. 78

The symptoms of LHC have been described in prospective studies. In a prospective study of 312 individuals diagnosed with COVID during the first pandemic wave in Norway, 55% reported symptoms 6 months following primary infection. The most common symptoms were fatigue

(30%), disturbed taste and/or smell (27%), concentration (19%) or memory (18%) problems,
dyspnea (15%), headache (11%), and palpitations (6%) (5). These symptoms are similar to those
reported by POTS sufferers, which include light-headedness, palpitations, tremulousness,
generalized weakness, blurred vision, chest pain, dyspnea, "brain-fog", and fatigue (6). Limited
systematic data exist regarding the hemodynamic, autonomic, or metabolic phenotypes in LHC,
or corresponding genotypic risk factors.

Consensus diagnostic criteria for POTS has been endorsed by numerous professional societies 88 (7). These criteria include chronic symptoms and a defined sustained increase in heart rate after 89 90 standing or head-up tilt. This heart rate increase should not be attributable to orthostatic 91 hypotension or other conditions that may provoke sinus tachycardia. Additionally, the 92 demonstrated increase in heart rate must coincide with the symptoms in question (such as light-93 headedness, palpitations, tremulousness, generalized weakness, blurred vision, and fatigue, vasovagal syncope). Additionally, consensus statements define diagnostic criteria for IST as the 94 95 presence of both average and absolute elevated resting sinus heart rate (8).

The present study will aim to further define risk factors for LHC and POTS/IST, better understand the underlying pathophysiology, estimate the proportion of individuals presenting with POTS symptoms who have the diagnosis, and evaluate an intervention (ivabradine) in a nested, randomized trial in those found to have POTS.

100 Evidence for LHC/POTS and Immunologic Dysregulation

While increasingly common, the pathophysiological mechanisms driving post-COVID-19
cardiovascular and autonomic complications, including tachycardia, remain unknown (9).
Nalbandian *et al* suggest that possible mechanistic pathways responsible for LHC include 1)

104 residual damage of cells and tissues caused directly by the SARS-CoV-2 infection, 2) expected 105 long-term damage due to critical illness, and 3) persistent immunological aberrations (10). Several mechanisms have been postulated by which immune dysfunction may contribute to 106 107 LHC. First, sustained inflammation, triggered by persistent virus, viral antigens, or immune dysregulation triggered by the initial infection, could directly cause cardiac damage (11). 108 Persistent immune activation can lead to cardiac fibrosis, and prolonged exposure to pro-109 110 inflammatory cytokines can prolong ventricular action potentials (12). Significantly for this study, chronic inflammation can also affect autonomic pathways (10). Second, individuals with 111 112 LHC may develop T-cell and/or natural killer (NK) cell exhaustion, defined as reduced cellular responses to SARS-CoV-2, and this can then lead to viral persistence and the symptoms of LHC. 113 Finally, COVID-19 may trigger development of autoantibodies, including antiphospholipid 114 115 antibodies or antibodies against adrenergic and muscarinic receptors, that could then contribute 116 to the cardiovascular manifestations of LHC (11, 13). Immunologic mechanisms discussed in the literature include persistent immune activation, T-cell/NK cell exhaustion, and development of 117 118 autoantibodies (10-14). The study will investigate whether other immune mechanisms play a role in contributing to post-COVID-19 POTS. Alterations in basophil and mast cell responsiveness 119 may influence development of POTS syndrome. One of the possible mechanisms underlying 120 121 POTS is activation of basephils and mast cells by parasympathetic neurons. This hypothesis is supported by a recent study where two thirds of individuals with POTS demonstrated increased 122 123 histamine or other mast cell mediators in the blood in the setting of postural tachycardia (15). The present study will investigate whether this also occurs in post COVID-19 POTS. 124 Biomarkers of mast cell and basophil degranulation, including histamine, tryptase, and 125 126 prostaglandin D2, will be measured before and after orthostasis testing. Additionally, participants

127 will be evaluated for increased basophil sensitivity to activation by calcitonin gene-related 128 peptide (CGRP) and substance P at baseline - molecules released by parasympathetic nerves that can stimulate mast cell and basophil activation. Immune complexes may be important drivers of 129 130 persistent inflammation after resolution of SARS-CoV-2 infection. Immune complexes are known to develop in the context of SARS-CoV-2 infection, and it has been demonstrated they 131 132 are able to persist in tissues and drive inflammation despite the resolution of viral infection (16, 17). Such immune complexes can interact with the mast cell via Fcy-receptor. These complexes 133 interact with a host of other immunological systems and affect NK cell activity. NK cell 134 135 responsiveness to immune complexes may be measured as well if indicated.

136 Evidence for LHC/POTS and Hematologic Dysfunction

In addition to immunologic dysregulation and cytokine storm, blood coagulation and 137 anticoagulant pathways, as well as fibrinolysis, are perturbed in COVID-19, increasing risks of 138 139 both macro/ micro-thrombosis and hemorrhagic pathologies with increasing infection severity 140 (18). Plasma or serum levels of fibrin D-dimer, a product of fibrinolysis, are now routinely 141 measured in clinical assays for COVID-19 patients, while assays for additional up- or down-142 regulated pro- and anti-coagulant proteins and their activities are still largely restricted to research laboratories. For example, the acute-phase protein von Willebrand factor (VWF) is 143 144 highly up-regulated in severe COVID-19, concomitant with reduced activity of the protease ADAMTS13, which cleaves VWF following its secretion from endothelial cells or platelets, 145 146 thereby reducing its prothrombotic potential (19, 20). Persistent endothelial damage is a feature 147 of LHC (21). Emerging evidence indicates that endotheliopathy and a prothrombotic phenotype 148 also persist in LHC (22). This includes altered thrombin lag times, endogenous potential and peak levels, as well as up-regulated VWF, factor VIII (FVIII) and thrombomodulin (23). 149

150 A recently published preprint reported that gamma prime fibrinogen (GPF), which is translated 151 from a splice variant of fibrinogen, is highly up-regulated in severe COVID-19 (22). 152 Interestingly, GPF binds to the heparin-binding exosite on thrombin, preventing its neutralization 153 by heparin and antithrombin III and increasing resistance of clots to fibrinolysis (24). It is hypothesized that GPF, like VWF and FVIII, may also be up-regulated in LHC. Further 154 155 characterizing altered hemostatic profiles in LHC could suggest more effective measures to 156 prevent thrombosis, e.g., potential effectiveness of direct thrombin inhibitors in patients with elevated GPF and/or who have failed low-molecular weight heparin therapy. 157

158 Psychosocial, Quality of Life, and Cognitive Factors

159 Despite a growing number of studies documenting the clinical impact of LHC, few have directly 160 examined the broad psychosocial and cognitive functioning impairments that may affect individuals who suffer from the condition (25). COVID-19, in the absence of the long-haul 161 162 syndrome, has been associated with numerous psychological symptoms including, but not 163 limited to psychological distress, post-traumatic stress disorder, secondary traumatic stress, 164 complicated grief, and anxiety (26-29). Not surprisingly, symptoms reported in the association with LHC are remarkably similar to many of the criteria for mood and anxiety disorders 165 166 described in the Diagnostic and Statistical Manual of the DSM, 5th edition (DSM-5) (30). For 167 example, heart palpitations, cognitive impairment, headache, sleep disturbance, dizziness, delirium, reduced appetite, and fatigue are also often present in several DSM-5 disorders. To 168 169 date, preliminary research on adults with LHC suggests that depression/anxiety, cognitive 170 impairment, loss of concentration, fatigue, and insomnia are common (31, 32). Importantly, this 171 research has also found that participants reported a significantly diminished quality of life. While there are clearly physiological underpinnings of COVID-19 contributing to symptoms during 172

acute illness, given the links between psychological functioning and COVID-19 that resolves, the
extent to which LHC is related to psychosocial and cognitive functioning warrants further
exploration.

176 Genetic and Phenotypic Assessments

genetic mechanisms responsible for COVID-19 177 Preliminary work has elucidated pathophysiology. The involvement of the cell surface receptor angiotensin converting enzyme 2 178 (ACE2) and the transmembrane protease serine-2 (TMPRSS2) protein in binding and cleavage of 179 180 SARS-CoV-2 has been reported in multiple studies (33). The association between the polymorphisms of renin-angiotensin-aldosterone system-related genes, i.e., ACE2 and 181 TMPRSS2, and the severity of COVID-19 disease have been thoroughly investigated (34). 182 Studies have correlated single nucleotide polymorphisms (SNPs) of ACE2 and TMPRSS2 with 183 lower severity of COVID-19 in an Indian population (35, 36), and a lower risk of developing 184 185 severe COVID-19 (37). Another meta-analysis found that a TMPRSS2 SNP was not associated with more severe COVID-19 manifestations, whereas two ACE2 SNPs were associated with 186 more severe COVID-19 manifestations by genotype but not allele (38). 187

A recent study identified that the ACE2 T allele was associated with a higher risk for critical COVID-19 c ACE2 with a higher risk of severe COVID-19 (41). Given ACE2 and TMPRSS2 polymorphism associations with severe COVID-19, the study will investigate associations with post-COVID symptoms including fatigue and dyspnea. These polymorphisms influence variability of ACE2 and TMPRSS2 expression with the ACE2 rs2285666 polymorphism elevating ACE2 expression up to 50%. Higher expression of ACE2 can trigger vascular constriction, worsening endothelial dysfunction, fibrosis and inflammation (42, 43).

195 Reports have noted elevated plasma ACE2 activity three months after the acute infection in 196 individuals with long-COVID as compared to uninfected matched controls (44). Long-lasting 197 systematic inflammation after acute SARS-CoV-2 is associated with more severe post-COVID 198 symptoms (45). These associations could underlie post-COVID symptoms (44). It is plausible 199 that intron/missense variants of ACE2 and TMPRSS2 polymorphisms could be associated with 200 LHC development.

Most studies investigating the role ACE2 or TMPRSS2 SNPs have focused on the risk of being 201 infected or the severity of COVID-19 disease in the acute phase. Two recent studies investigated 202 the association between five COVID-19 associated SNPs in AC1, ACE2 and TMPRSS2 and 203 204 long term post-COVID symptoms in previously hospitalized COVID-19 survivors (46, 47). 205 However, the SNPs assessed, although previously associated with COVID-19 severity, did not 206 predispose for developing LHC symptoms in people who were previously hospitalized due to 207 COVID-19. To date, data on genomic associations and predispositions with the development of LHC remain limited. Strong correlation between disease severity and predisposition to LHC 208 209 have not been established. Genetic susceptibility to endophenotypes overlapping with LHC may 210 contribute to the condition spectrum. The study aims to evaluate polygenic risk factors across medical phenotypes, including cardiovascular, hematologic, immunologic and neurological 211 conditions, for enrichment in POTS/IST subjects from whole genome sequencing and multi-omic 212 213 signature analysis. Multi-omic profiling aims to enable molecular classification of POTS/IST 214 subgroups from transcriptome and proteome expression of key host and disease factors.

215 Management of POTS

216 Postural Orthostatic Tachycardia Syndrome (POTS) occurs frequently in patients with LHC. There is currently no agreed upon standard of care for POTS. Rate control medications have 217 218 been studied, as have exercise training and other medications. Low-dose propranolol was 219 previously recommended based on a trial performed at Vanderbilt. A subsequent study by a different group, however, found no improvement in quality of life when using propranolol (48). 220 221 Propranolol, the recommended agent, is associated with penetration of the central nervous 222 system resulting in nightmares and depression. Bronchospasm is a common (and sometimes life-223 threatening) complication.

224 In a recent review of POTS (2020), the Canadian Cardiovascular Society acknowledged that case 225 series of ivabradine in POTS have been reported to have 68-78% effectiveness with respect to 226 controlling heart rate and symptoms (49). Ivabradine is a selective sinoatrial node blocker FDA-227 approved for management of tachycardia associated with stable angina and heart failure not fully 228 managed by beta blockers. It blocks the hyperpolarization-activated cyclic nucleotide-gated 229 (HCN) channel responsible for the cardiac pacemaker I_{funny} current, which regulates heart rate. In 230 clinical electrophysiology studies, cardiac effects were most pronounced at the sinoatrial (SA) 231 node, with lesser prolongation of the AH and PR intervals. There was no effect on ventricular 232 repolarization or myocardial contractility. Ivabradine causes a dose-dependent reduction in heart 233 rate in proportion to the baseline heart rate. Ivabradine's relative lack of effect on the respiratory 234 system may avoid exacerbating dyspnea experienced by LHC patients. This has been confirmed in a small RCT of patients with postural orthostatic tachycardia syndrome (POTS) where it was 235 236 shown to safely reduce heart rate (50). Other treatments, including salt supplementation, 237 midodrine, and fludricortisone may soon be superseded by this novel therapy. IST is a similarly

intractable clinical condition that is believed to be responsive to ivabradine, although the drugdoes not have FDA approval for that indication.

240

241 Methods/Design

242 Aims and Objectives

This prospective study of 200 LHC volunteers with a nested RCT will assess the effect of ivabradine on heart rate and symptoms in those meeting diagnostic criteria for POTS or IST. A comparator group of 50 volunteers with documented COVID-19 but without LHC will help identify the risk factors for LHC and autonomic dysfunction. The comparator group will also be evaluated for POTS and eligible for inclusion in the nested RCT.

248 The primary aim is to identify the proportion of volunteers with relevant symptoms diagnosed 249 with postural orthostatic tachycardia syndrome (POTS) or inappropriate sinus tachycardia (IST). We will first attempt to address the frequency of clinically confirmed POTS in those with 250 251 persistent COVID-19 symptoms suggestive of autonomic dysfunction. The second aim is to 252 determine the potential benefits of ivabradine treatment for those with LHC-associated POTS or 253 A nested clinical trial for Ivabradine responsiveness on reduction of tachycardia. IST. 254 Ivabradine is a drug approved to treat tachycardia in severe heart failure with some demonstrated improvement in POTS outcomes.ⁱⁱ Those with confirmed POTS or IST will be randomized to 255 ivabradine or placebo to determine efficacy in reducing heart rate and POTS symptoms. 256

The third aim is to characterize potential differences in hematologic, metabolic, immunologic, and genetic variants among volunteers with and without LHC. Cellular and molecular characterization of LHC and non-LHC participants will be performed. This aim will identify

risk factors and provide mechanistic insights into the pathophysiology of LHC and POTS for those with and without LHC. The biopsychosocial mechanisms of LHC and POTS will also be explored. Study objectives are summarized in Table 1.

263 Ethical Approval

The study was approved by the Uniformed Services University of the Health Sciences Institutional Review Board in June 2022 and registered with clinicaltrials.gov as NCT05481177. The study will adhere to the principles of Good Clinical Practice.

267 Study design

The study design is shown in Figure 1. The study will enroll a cohort of 200 volunteers with LHC from both the Military Health System (MHS) and civilian populations in the Washington metropolitan area (which includes the District of Columbia and parts of Maryland, Virginia, and West Virginia). In addition, a small comparator group of 50 volunteers with a confirmed COVID-19 diagnosis but without ongoing sequelae will be enrolled in the overall cohort.

273 Study Site and Population

274 The study will take place at a single center in suburban Maryland. The cohort will be enriched 275 for volunteers with one or more signs or symptoms consistent with autonomic dysfunction 276 indicating potential POTS/IST during the recruiting process. Examples include dizziness, heart 277 palpitations, fainting spells or racing heart rate. Other non-specific symptoms associated with 278 POTS have included headache, 'brain fog' or confusion, gastrointestinal disturbances, and 279 fatigue. Inclusion criteria are: 18-80 years old; History of documented COVID-19 infection of any severity to include a positive COVID-19 PCR, or antibody test; meet criteria for 'long-haul' 280 281 COVID-19 with persistent symptoms >12 weeks following acute illness for the LHC cohort (or 282 without persistent long-haul COVID-19 symptoms for the non-LHC cohort); able and willing to provide informed consent and participate for the 1-year study duration; Willing to participate in 283 284 the nested Ivabradine RCT if enrollment criteria are met; and access to healthcare and health insurance. 285

286 Exclusion criteria are resting heart rate <60 bpm; atrial fibrillation; supraventricular tachycardia; 287 allergic reaction or known contraindications to study drug; pregnant/lactating females; impaired gastrointestinal drug absorption; acute suicidality identified at screening; taking any of the 288 289 following unless discontinued in consultation with the volunteer's healthcare provider and a one-290 week washout period: beta-blockers, calcium-channel blockers, cholinesterase inhibitors (pyridostigmine), vasoconstrictors (midodrine, octreotide, droxidopa, stimulants), sympatholytics 291 292 (clonidine, methyldopa), blood volume enhancers (fludrocortisone, desmopressin, salt 293 supplementation), or oral ketoconazole.

294

295

296 Detailed Study Methods

297 Study methods are described in detail in Figure 2 and the accompanying Spirit Figure (Figure 298 3). Following informed consent, volunteers will be screened to determine whether they meet the 299 study enrollment criteria. Initial screening will include medical history including concomitant 300 medications, and physical exam, structured clinical interview for DSM-5 psychiatric disorders, COVID-19 antibody tests, EKG, baseline spirometry to assess pulmonary function, and clinical 301 safety laboratory testing to include serum chemistries, complete blood count, and urinalysis. 302 303 Subjects will have thyroid functions tests (TFTs), highly sensitive C-reactive protein (CRP), cardiac specific troponins and pro-BNP levels (the latter to assess for myocarditis) at screening 304 only. Females will have a urine test for β -hCG at screening, and if positive, serum β -hCG 305 (Figure 2 and 3). The initial screening will be valid for 60 days prior to participation in a nested 306 randomized placebo-controlled trial of ivabradine to reduce heart rate and improve symptoms 307 308 (nested RCT).

After the initial Cohort Screening visit, volunteers meeting criteria will return for enrollment into 309 310 the overall LHC cohort and screening for the nested RCT (visit 2). Enrolled volunteers will 311 undergo whole genome sequence analysis to look for biomarkers of LHC risk, along with multiomic analysis. Volunteers will have orthostatic vital signs, an interval medical history, EKG, 312 immunologic assays, psychosocial, quality of life, and cognitive surveys; complete cognitive 313 314 performance tasks; undergo metabolic testing, and have concomitant medications reviewed. Volunteers enrolled to the overall study cohort will be screened for enrollment in the nested RCT 315 for POTS. Volunteers will be provided with ambulatory electrocardiographic and vital signs 316 317 monitoring devices at enrollment, and complete of a detailed symptom diary for review by study

318 investigators after 1 week of monitoring. Investigators will determine whether volunteers meet 319 criteria to participate in the nested (RCT) of ivabradine to reduce heart rate and improve POTS symptoms. The inclusion criteria for the nested RCT are the same as the overall cohort plus: 320 321 POTS diagnosed based on increased heart rate from supine to standing > 30 beats per minute and < 20 mm Hg drop in systolic or <10 mmHg drop in diastolic blood pressure. 322 Volunteers diagnosed with IST with or without LHC based on a 24-hour mean heart rate of 90 beats per 323 minute or more (in sinus rhythm) will also be included. Females of childbearing age must be 324 willing to use a highly effective form of contraceptive with <1% failure rate or practice 325 326 abstinence for the RCT duration.

327 Treatment Intervention

Ivabradine (Procoralan) at a starting dose of 5mg twice per day will be compared to placebo in addition to otherwise appropriate medical care. The dose will be adjusted based on individual heart rate response in accordance with the approved product label.

Randomization, Allocation, and Blinding

332 Study drug will be allocated to treatment groups by an unblinded research pharmacist. Treatment 333 allocation and randomization will be determined in advance using time-blocked randomization 334 with blocks of three. Allocation will be concealed from the volunteers and study team with treatment assignments predetermined by unblinded personnel not otherwise engaged in study 335 336 procedures. Test article will be concealed from both subjects and investigators by placing 337 medications at predetermined doses in gel capsules. For active treatment, 2.5mg dose units will be encapsulated with a pharmaceutically inactive compound (e.g. microcrystalline cellulose), 338 339 while the placebo group will receive capsules with only the inactive compound.

340 **Data Collection**

341 *Clinical Assessments*

Orthostatic vital signs will be collected with volunteers sitting, standing, and lying down with 5 342 343 minutes between each measurement. Head-up tilt-table (HUTT) testing will be performed with the volunteer in the fasted state with heart rate and blood pressure monitoring. HUTT will be 344 345 considered abnormal if the volunteer has an increase in heart rate of 30 beats per minute over baseline with accompanying symptoms of orthostatic intolerance. A history and physical exam 346 347 at screening will include demographics (age, sex, race, ethnicity), medical history to include documenting the volunteer's history of COVID-19, vital signs and clinically significant 348 abnormal physical findings. A brief interval medical history and targeted physical exam to 349 include adverse event assessment will be performed at subsequent visits. Adverse events for 350 351 those enrolled in the RCT will be assessed for severity and treatment relatedness using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 352

Volunteers will have supine 12 lead electrocardiograms after a five-minute period of rest. 353 Continuous ambulatory blood pressure and electrocardiographic monitoring will be measured 354 using appropriate FDA-cleared device(s). Subjects enrolled to the nested RCT will continue to 355 356 have these assessments during the study through month 3. Subjects not enrolled to the RCT will have these performed for 1 week starting at the second screening visit for the nested RCT and 1 357 358 week at least 2 weeks prior to study discharge. Volunteers will maintain a cardiac symptom diary 359 while they have ambulatory EKG and vital signs monitoring. Spirometry will be performed to 360 assess pulmonary function along with a Dyspnea-12 score which will serve as a key indicator of 361 potential confounding by residual and/or pre-existing respiratory illness. An echocardiogram

will be performed at baseline for all those enrolled to the nested RCT to exclude subjects with
left ventricular ejection fractions <40%.

364 Dose Adjustment

For those enrolled in the RCT, ivabradine dose will be adjusted based on treatment response according to the label. Those taking placebo will have adjustments made using test article intended to match active treatment based on appearance.

368 Psychosocial, Quality of Life, and Cognitive Factors Assessment

Volunteers will complete a series psychosocial and quality of life of surveys. The Short Form 369 370 Health Survey (SF-36 v2) includes coherent and easily administered items evaluating quality of life in physical, emotional, and social domains (51). The Patient Health Questionnaire-SADS 371 (PHQ-SADS) is a 30-item self-report measure incorporating items from the PHQ-8 (depression 372 373 symptoms), GAD-7 (generalized anxiety disorder symptoms), and PHQ-15 (somatic symptoms) 374 (52). Volunteers also will complete the self-report Depression Anxiety Stress Scale-21 (DASS-21) (53), a questionnaire assessing stress, depression, and anxiety symptoms experienced during 375 the past week. The Patient-Reported Outcomes Measurement Information System (PROMIS) 376 377 Cognitive Function Short Form-8a will assess perceived cognitive function over the past week 378 (54). Modules from the Structured Clinical Interview for DSM-5 disorders – research version (SCID-5-RV) will be used to evaluate psychiatric disorders (e.g., mood, anxiety, somatic 379 380 disorders, etc.) and assess possible psychological bases for somatic complaints (55). Finally 381 volunteers will complete the NIH Toolbox Cognition Battery (56), a series of cognitive tasks to 382 assess working memory, episodic memory, immediate recall, processing speed, attention, and executive function. (Figure 2 and 3.) 383

384 Hematology Assays

Clinical and research laboratory assays (PT, APTT, factor VIII:C, total fibrinogen, D-dimer, thrombin generation assay and thromboelastometry (ROTEM), gamma prime fibrinogen, von Willebrand factor (VWF) antigen, VWF propeptide, ADAMTS13 activity and soluble thrombomodulin) will quantify and characterize specific markers of dysregulated coagulation and immunothrombosis.

390 Genomic Analysis

PAXGene Blood tubes will be collected for genomic and transcriptomic profiling. For whole 391 392 genome sequencing, genomic DNA will be isolated and used as input for PCR-free library preparation using a ligation-based method on automated liquid handling platforms. Sequencing 393 libraries will be sequenced using Illumina NovaSeq 6000 platforms with paired-end 150bp reads. 394 Raw reads will be demuxed, aligned to a reference genome and genomic variants will be called 395 using a DRAGENv4.0 graph genome and machine learning enabled pipeline. Variants will be 396 397 annotated and interpreted using a phenotype-award pipeline using Genomiser and used as input for polygenic risk score calculation from selected polygenic score sources from the PGS catalog 398 and used for comparative analysis with control-matched general population scores to identify 399 400 candidate traits associated with POTS/ITS.

401 Multi-omic Assays

402 Peripheral blood mononuclear cells (PBMCs) will be collected to assess for transcription,
403 translation and expression of key host and disease factors. Metabolomics will be evaluated along
404 with transcriptome and plasma for proteomics.

405 Immunologic Assays

406 Serology and cytokines will be assessed in serum, with PBMCs collected for cell-based 407 immunity assays to potentially include studies of T and NK cells. Plasma levels of histamine, tryptase, and prostaglandin D2 will be measured 15 minutes before and shortly after orthostasis 408 409 testing to assess for mast cell and basophil degranulation. Additionally, biomarker levels including IL-1 receptor antagonist (IL-1Ra), adiponectin, and cholinesterases may be evaluated 410 411 at baseline while participants are in the supine position to determine if these inflammatory and metabolic markers are altered in individuals with LHC and POTS. These measurements will be 412 made on the same plasma samples but only in the supine position. 413

414 Basophil Activation in Response to CGRP and Substance P

Basophil Activation in response to CGRP and substance P, as well as basophil sensitivity to activation via the IgE signaling pathway, will be measured before starting the study drug and prior to orthostasis testing. Activation assays may be repeated at the 3-month time point.

418 Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis

Drug levels of ivabradine and relevant metabolites will be analyzed. Results will not be included in the study database until after the first 3 months of the study have been completed for all nested RCT subjects to maintain blinding. For those subjects assigned to placebo, at the completion of 3 months, individuals will be offered cross-over to active drug with participation in a rich-PK sampling study to establish population PK-PD data for ivabradine. The first dose of ivabradine (5mg) will be administered followed by serial blood PK specimens at pre-dose (0 hour; within 1 hour prior to dosing), and at 0.25, 0.5, 1, 2, 4, 8 and 24 hours after dosing.

426 Unblinded Data Safety Monitoring Board (DSMB) Assessment

Individual treatment effectiveness will be assessed on a rolling basis by an independent, unblinded DSMB as nested RCT subjects approach completion of the first 3 months of the study. Placebo-treated volunteers will be offered treatment at month 3 with an additional 9 months of follow-up. Treated subjects will be evaluated for treatment benefit and continued at the identified effective dose as appropriate. The DSMB will include the Research Monitor and 3 physicians.

432 Data Storage and Handling

Study data will be recorded in electronic case report forms (CRFs) using the Research Electronic
Data Capture system (REDCap). De-identified data will be directly captured from diagnostic
devices including ultrasound images, continuous ambulatory vital signs and/or cardiac telemetry
locally stored on password-protected devices.

437 Sample Size Justification and Statistical Analysis

438 Up to 200 evaluable subjects will be enrolled in the general LHC cohort. Study recruiting will be implemented to enrich for volunteers with common clinical features of POTS. At least 20% of 439 440 those recruited are expected to have appropriate POTS or IST symptoms for enrollment to the nested RCT (ivabradine vs. placebo). The design is estimated to yield an RCT study population 441 of at least 40 evaluable subjects. Drop-outs in all cohorts may be replaced. With at least 36 442 443 subjects completing the RCT at 2:1 allocation of treatment to placebo, the study will have 80% power to identify a difference in standing heart rate at 3 months from 90 bpm in the placebo 444 group compared to 80 bpm in the treated group at the 0.05 significance level. 445

446 Data will be analyzed using Stata, R, or another equivalent statistical computing package.
447 Participant demographic and clinical characteristics will be characterized. Percentages and
448 means (with standard deviations) will be calculated for categorical and continuous variables,

respectively. We will assess differences in characteristic distribution by group using Chi-square and t-tests (or Fisher's exact test for small sample sizes) as appropriate. Group differences will be determined for outcomes using multilevel linear (for continuous variables) and logistic regression models. Results will be reported using odds ratios (ORs) for binary outcomes and regression coefficients for continuous outcomes. Association estimates will include 95% CIs. A two-tailed error rate of $\alpha = .05$ will be the threshold for statistical significance.

455

456 **Discussion**

Since the initial reports emerged on autonomic dysfunction associated with long-haul COVID-19, substantial progress has been made in better characterizing associated sequelae. Despite these recent gains, a great deal remains poorly understood regarding how best to evaluate and treat a lengthy list of potential symptoms and syndromes (4, 57). Amidst this quandary, POTS has emerged as the most common form of autonomic dysfunction associated with LHC, with as many as 2.5% of those with LHC affected (58). Pre-COVID, longitudinal studies revealed that while often self-limited, residual POTS symptoms may persist for 5 years or longer.

Despite diagnostic advances, efforts to differentiate POTS from other autonomic syndromes remain imperfect. This is due in part to the wide array of organ systems and functions controlled by the autonomic nervous system (ANS). The most common cardiovascular findings may include tachycardia and hypertension from increased sympathetic tone, orthostatic hypotension from decreased baroreceptor and chemoreceptor reflex sensitivity, and reduced heart rate variability (59). Commonly recommended clinical diagnostic tests to evaluate autonomic dysfunction include Valsalva maneuvers, supine and standing vital signs measurements or head-

up tilt table testing (HUTT), a 6-minute walk test, deep breathing, and ambulatory EKG testing. 471 472 Other tests including skin biopsies for evaluation of peripheral nerve inflammation, and 473 emerging wearable device measurements have also been suggested. A range of questionnaires 474 have also been employed including the COMPASS-31, Vanderbilt Orthostatics Symptom Score (VOSS), PROMIS-29, and others (58). In the present study, we have selected a subset of tests in 475 the interests of time, simplicity, and the ability to enroll and retain subjects. Planned tests include 476 477 HUTT (or supine/standing vital signs for those unable to complete HUTT), ambulatory EKG monitoring, and the COMPASS-31 survey for autonomic dysfunction. Volunteers will be 478 479 monitored using an advanced automated ambulatory vital signs monitor recently approved by 480 FDA in order to aid in diagnosis (60).

Difficulties in diagnosis can compound the disability and demoralization suffered by POTS 481 482 patients. An estimated 10% of POTS sufferers may be unable to return to work and 40% have 483 residual deficits (61). The present study will prospectively evaluate 200 LHC volunteers with a nested RCT to assess the impact of ivabradine on heart rate and symptoms in those meeting 484 485 diagnostic criteria for two important types of autonomic dysfunction, POTS and inappropriate 486 sinus tachycardia (IST). Our approach will include an integrated clinical, psychological and laboratory evaluation of a cohort of patients enriched for symptoms and signs consistent with 487 autonomic dysfunction. A comparator group of 50 volunteers with documented COVID-19 but 488 without LHC will be enrolled to better identify the risk factors for LHC and autonomic 489 490 dysfunction. The comparator group will also be evaluated for POTS/IST and eligible for inclusion in the nested RCT if present. 491

492 A large number of interventions have been proposed for POTS. Standard of care remains limited 493 and currently includes remedies such as compression garments, hydration and fludrocortisone to treat hypotolemia, drugs like midodrine to treat hypotension, and propranolol for tachycardia 494 495 and increased sympathetic tone. Among other proposed experimental interventions such as intravenous immune globulin as a general anti-inflammatory and SSRIs for affective 496 components, ivabradine has been proposed to lower heart rate and alleviate associated 497 Ivabradine is a unique specific modulator of sinus node automaticity that acts 498 symptoms. through specific blockade of the I_{funny} channel, whose expression is relatively restricted to 499 500 cardiac nodal tissue. Other commonly used rate lowering agents including beta blockers and non-501 dihydropyridine calcium channel blockers have off-target effects on cardiac contractility, blood pressure and/or bronchial tone. Limited evidence to date indicates that ivabradine may be 502 503 effective for both POTS and IST by reducing inappropriately elevated heart rate in these 504 conditions. Nevertheless, most of the data regarding ivabradine in POTS is anecdotal, with one 505 small RCT demonstrating benefit to date (50). This study will add to the understanding of the 506 potential therapeutic value of ivabradine in post-viral dysautonomia. Ivabradine's current scope 507 remains limited to the management of tachycardia associated with stable angina and heart failure not fully managed by beta blockers. 508

In addition to the primary aims, the study will contribute to identifying risk factors and better understanding pathophysiological processes, laying the groundwork for further exploration. The pathophysiologic basis and underlying mechanisms of disease remain poorly defined at present, though recent progress has been made (44). In the present study, we aim to take a multidisciplinary approach to better understand the diagnosis and management of LHCassociated POTS. LHC/POTS is believed to be caused by multiple pathophysiological processes

515 including immune dysregulation, hematologic dysfunction, and dysautonomia. In our study, the 516 risk factor evaluation will assess for hematological, immunological, and metabolic anomalies 517 underlying the development of autonomic dysregulation. Genomic and multi-omic analysis will 518 probe for genotypic and phenotypic risk factors for dysautonomia. Furthermore, symptoms of POTS/IST remain broadly heterogeneous, including overlapping psychological and psychiatric 519 520 manifestations, for e.g., insomnia, depression, fatigue, memory loss. The study will incorporate 521 evaluation of psychosocial, quality of life, and cognitive factors to better understand psychological and cognitive symptoms, and determine their interplay with physiologic responses 522 to LHC. 523

Study of a complex disease with an intricate follow-up plan is bound to face practical 524 525 implementation challenges. First, there is no established consensus for LHC diagnosis. Nonspecific symptoms such as fatigue might not prompt patients to seek medical care. As a result, 526 LHC remains an underdiagnosed condition, thus, reducing the pool of potential patients available 527 528 for recruitment. We aim to overcome this challenge through use of a comprehensive diagnostic 529 strategy, to include the use of ambulatory measurements. Our recruitment strategy aims to 530 combine community outreach including local healthcare providers to effectively identify and 531 refer potential participants. Compliance with a host of study procedures and visits is a generic 532 challenge for clinical research but may be compounded by disability and other challenges faced 533 by POTS sufferers. Appropriate guidance and participant education will be key in ensuring 534 successful adherence. The diagnostic complexity of POTS and related dysautonomia syndromes is also a potential limitation, as we have opted for an implementable subset of diagnostic tests 535 536 from among the wide array available. Our hope is that use of multiple modalities to include 537 ambulatory monitoring will ensure an adequate number of volunteers are enrolled in the RCT.

We estimate 20-25% of those with POTS-like symptoms presenting for the study will actually have POTS, but these could prove to be substantial over- or under-estimates. Blinding a study using a rate-lowering agent may be challenging as well, particularly where placebo-treated subjects experience no benefit and are at risk for non-compliance or drop-out.

The management of LHC-associated POTS, a complex multifactorial condition, remains an emerging area of study and an ongoing challenge for patients and clinicians alike. The present study aims to add to the rapidly expanding LHC knowledge base, and explore one of several proposed interventions for LHC-associated cardiovascular autonomic dysfunction. We aim to accurately assess the effectiveness of ivabradine and its proper use in the management of LHC complicated by POTS. In so doing, we hope to provide a more solid evidence base for those struggling with this debilitating condition.

549 Trial status

550 This study is conducted under protocol IRB # USUHS.2022-094 approved in April 2022. The 551 recruitment began on May 5^{th} 2023 and is expected to be completed within a year in May 2024.

552

553

- 555
- 556
- 557

560 Table 1. COVIVA Study Objectives.

Objectives	Study Endpoints/Milestones
1. Assess frequency and severity of fatigue, dyspnea, headache, confusion and other suggestive symptoms in volunteers with and without LHC; measure occurrence of clinically confirmed POTS or IST—in relation to symptoms	Proportions of LHC and non-LHC volunteers with POTS; disease severity based on composite physiologic (ambulatory EKG, vital signs, orthostatics, Objective 3) and well-being assessments (Objective 5)
2. Assess whether treatment with ivabradine will significantly reduce heart rate; improve symptoms and quality of life among volunteer with POTS or similar dysautonomia	Primary endpoint for the nested ivabradine RCT - reduction in standing heart rate at three months. A small cross-over RCT in POTS patients without COVID-19 history found ivabradine reduced standing heart rate ~16 bpm between treated and placebo groups (see text)
3. Determine whether wearable automated ambulatory monitoring with existing FDA- approved devices will improve diagnostic accuracy for POTS	The differential proportion of individuals diagnosed with POTS using conventional (in-office) and wearable diagnostic methods
4. Determine the degree to which LHC induces autonomic instability and its associations with induced inflammation and/or dysregulation	Degree and severity of POTS as in Objectives 1 and 3. Levels of circulating catecholamines before and after orthostatic maneuvers
5. Evaluate potential contribution of psychological symptoms and interplay between psychosocial and cognitive symptoms, quality of life, and physiologic responses induced by LHC	Changes in quality of life (SF-36); psychosocial functioning (PHQ-SADS, DASS-21 surveys); Structured Clinical Interview for DSM-5 disorders; cognitive function (PROMIS, NIH Toolbox)
6. Determine if LHC improves following subsequent vaccination and/or "breakthrough" COVID-19 infection	Changes in quality of life, symptom surveys and/or laboratory markers of infection in those vaccinated or contracting infection during the study

7. Compare antibody and/or cellular immune responses to SARS-CoV-2 antigens in LHC patients and infected individuals without LHC	1. IgG antibodies to SARS-CoV-2 or the four major seasonal human coronaviruses (HCoV-OC43, HCoV-HKU1, HCoV- 229E, or HCoV-NL63)
	2. T-cell cytokine responses against SARS-CoV-2
	3. Evaluate whether individuals with LHC have decreased immunoregulatory networks compared to infected individuals without LHC
	4. Assess NK cell phenotypic/functional differences
	5. Identify if POTS-related orthostasis is associated with mast cell degranulation and basophil activation product release (histamine, tryptase)
	6. Evaluate whether basophil responsiveness to activation in response to mediators released by parasympathetic nerves (Calcitonin gene-related peptide (CGRP), Substance P) is different between individuals with POTS and those without.
8. Assess whether markers of dysregulated blood coagulation (significantly correlated with immunothrombosis in severe COVID- 19) persist in individuals with LHC	PT, APTT, factor VIII:C, total fibrinogen, D-dimer, thrombin generation, thromboelastometry (ROTEM); Exploratory - gammaprime fibrinogen, von Willebrand factor (VWF) antigen, VWF propeptide, ADAMTS13 activity, soluble thrombomodulin

562

563

564 **Figure Legends**

Figure 1. Overall Study Schema. A diagram of the general study design. The study will include an observational cohort with 250 volunteers including 200 with long-haul COVID and 50 controls without LHC. Those from the observational cohort who are diagnosed with POTS will be randomized to a nested, placebo-controlled trial of ivabradine to control heart rate and improve symptoms. (POTS - Postural Orthostatic Tachycardia Syndrome; IST - Inappropriate Sinus Tachycardia; IVA - Ivabradine; SXS - Symptoms; HR - Heart Rate; BP - Blood Pressure).

572	Figure 2. COVIVA Study Schedule of Events. A listing of times and events for study procedures.
573	
574	Figure 3. COVIVA Study Spirit Figure
575	
576	
577	
578	
579	List of abbreviations
580	ACE: Angiotensin Converting Enzyme
581	ANS: Autonomic Nervous System
582	CBC: Cell Blood Count
583	CGRP: Calcitonin Gene-Related Peptide
584	CIs: Confidence Intervals
585	CTCAE: Common Terminology Criteria for Adverse Events
586	COMPASS: Composite Autonomic Symptom Score
587	COVID-19: Coronavirus Disease 2019
588	CRFs: Case Report Forms
589	CRP: C - Reactive Protein
590	DASS-21: Depression Anxiety Stress Scale-21

- 591 DSMB: Data Safety Monitoring Board
- 592 DNA: Deoxyribonucleic Acid
- 593 DSM-V: Diagnostic and Statistical Manual of the DSM, 5th edition
- 594 EKG: Electrocardiogram
- 595 GAD: Generalized Anxiety Disorder
- 596 GPF: Gamma Prime Fibrinogen
- 597 FDA: Food and Drug Administration
- 598 HCN: Hyperpolarization-Activated Cyclic Nucleotide-Gated
- 599 HUTT: Head-Up Tilt-Table
- 600 IST: Inappropriate Sinus Tachycardia
- 601 LHC: Long-Haul' COVID-19
- 602 MSAS: Memorial Symptom Assessment Scale
- 603 MHS: Military Health System
- 604 NIH: National Institutes of Health
- 605 NK: Natural Killer
- 606 ORs: Odds Ratios
- 607 PBMCs: Peripheral Blood Mononuclear Cells
- 608 PHQ: Patient Health Questionnaire

- 609 POTS: Postural Orthostatic Tachycardia Syndrome
- 610 PT: Prothrombin Time
- 611 PTT: Partial Thromboplastin Time
- 612 PROMIS: Patient-Reported Outcomes Measurement Information System
- 613 RCT: Randomized Controlled Trial
- 614 REDCap: Research Electronic Data Capture system
- 615 SA: Sinoatrial
- 616 SCID-5: Structured Clinical Interview for DSM-5 Disorders
- 617 SF-36: Short Form Health Survey
- 618 SNPs: Single Nucleotide Polymorphisms
- 619 TFTs: Thyroid Functions Tests
- 620 TMPRSS2: Transmembrane Protease Serine-2
- 621 VOSS: Vanderbilt Orthostatics Symptom Score
- 622 VWF: Von Willebrand Factor
- 623
- 624 **Declarations**
- 625 *Ethics approval and consent to participate*
- 626 The study was approved by the Uniformed Services University of the Health Sciences
- 627 Institutional Review Board in June 2022 and registered with clinicaltrials.gov as NCT05481177.

- 628 Written informed consent will be obtained from all participants. A copy of the ethical approval
- and consent have been submitted as an additional file.
- 630 *Consent for publication*
- 631 Not applicable.

632 Competing Interest

633 The authors have no conflicts of interest to disclose.

634 *Funding*

This study is funded by the Defense Health Agency (DHA), Department of Defense through the Uniformed Services University. Funds to perform the study were awarded through Cooperative Agreements with The Metis Foundation (Award # HU00012120090) and Henry M. Jackson Foundation for the Advancement of Military Medicine (Award # HU00012120087). The Funder has no role in the in study design; collection, management, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication.

641 *Author's contribution*

DS is the Principal Investigator and MH the Protocol Chair and grant awardee; they conceived the study, led the proposal and protocol development and drafted the manuscript. TA, JL, DB, KA, LH, RM, BM, DS, KP, PK, ME, AM, MTK, EG, EM, KP and CD assisted in the design of the development of the protocol as well as editing of the manuscript. DS, MH, BM, RM and STL drafted and edited the manuscript. MH supervised the design and implementation of the study and edited the manuscript. All authors read and approved the final manuscript.

648 Acknowledgements

649 The authors would like to acknowledge our colleagues without whom the study would not have 650 been possible. From the Uniformed Services University Drs. Jacob Collen, Marian Tanofsky-651 Kraft, Ian Stewart, Paige Waterman, Martin Evans, Benjamin Pierson, Milissa Jones, Monique 652 Hollis-Perry, Agnes Montgomery, Vivian Bauman, Katherine Thompson; Ms. Austin Pagani, Annette Cunningham, and Debra Weed. From the US Army Medical Research Institute of 653 Infectious Diseases - Drs. Phillip Pittman, Erin Tompkins, Fernando Guerena and Ms. Carolyn 654 655 Holland. From the Henry M. Jackson Foundation for the Advancement of Military Medicine 656 Ms. Priscilla Kobi, Laurie Coran, Raquel Martinez, Heidi Adams, and Tabitha Shipmon. From the Metis Foundation - Marlene Barrera, Stephanie Margaret Mayne, Timothy Suzich, Joya 657 658 Libbus, Keiko Fox, Holly Spinner, Isabel Thorstad, Hannah Repke, and Ashlee Simmons. From the Walter Reed Army Institute of Research Dr. Daniel Selig. From the Armed Forces Research 659 660 Institute of Medical Sciences Drs. Pattaraporn Vanachayangul and Jeffrey Livezey. From the Walter Reed National Military Medical Center Drs. Jessica Wong-Flores, Nikhil Hauprikar and 661 662 Wesley Campbell, and Mr. Victor Buckwold. From the US Army Research Institute of 663 Environmental Medicine Dr. Geoff Chin and from the Joint Program Executive Office of Chemical and Biological Defense Dr. Anthony Cardile. 664

666 **References**

667

- 1. Long CVID or POST-COVID Conditions. <u>https://www.cdc.gov/coronavirus/2019-</u>
- 669 <u>ncov/long-term-</u>
- 670 <u>effects/index.html?s_cid=11840:long%20term%20covid:sem.ga:p:RG:GM:gen:PTN:FY23</u>.
- 671 Accessed 29 March 2023.

672 2. Mar PL, Raj SR. Postural Orthostatic Tachycardia Syndrome: Mechanisms and New

673 Therapies. Annu Rev Med. 2020;71:235-48. doi: 10.1146/annurev-med-041818-011630. Epub

674 2019 Aug 14. PMID: 31412221.

675 3. Is POTS a Long-Haul Post-COVID-19 Symptom? <u>https://www.acc.org/latest-in-</u>
676 <u>cardiology/articles/2021/03/10/20/13/is-pots-a-long-haul-post-covid-19-symptom</u>. Accessed 29
677 March 2023.

4. Raj SR, Arnold AC, Barboi A. Long-COVID postural tachycardia syndrome: an
American Autonomic Society statement. Clin Auton Res. 2021;31(3):365-8. doi:
10.1007/s10286-021-00798-2. Epub 2021 Mar 19. PMID: 33740207; PMCID: PMC7976723.

5. Blomberg B, Mohn KG, Brokstad KA. COVID in a prospective cohort of home-isolated
patients. Nat Med. 2021;27(9):1607-13. doi: 10.1038/s41591-021-01433-3. Epub 2021 Jun 23.
PMID: 34163090; PMCID: PMC8440190.

6. Grubb BP. Autonomic Dysfunction as a Consequence of COVID-19 Infection: A New
685 Twist on an Old Problem. J Am Coll Cardiol. 2022;79(23):1331-2332. doi:
686 10.1016/j.jacc.2022.04.007. PMID: 35680184; PMCID: PMC8972341.

Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology
and management. J Intern Med. 2019;285(4):352-66. doi: 10.1111/joim.12852. Epub 2018 Nov
23. PMID: 30372565.

690 8. Sheldon RS, Grubb BP 2nd, Olshansky B. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus 691 vasovagal syncope. 692 tachycardia, and Rhythm. 2015;12(6):41-63. doi: Heart 10.1016/j.hrthm.2015.03.029. Epub 2015 May 14. PMID: 25980576; PMCID: PMC5267948 693

9. Dixit NM, Churchill A, Nsair A. Post-Acute COVID-19 Syndrome and the
cardiovascular system: What is known? Heart J Plus. 2021;5:100025. doi:
10.1016/j.ahjo.2021.100025. Epub 2021 Jun 24. PMID: 34192289; PMCID: PMC8223036.

Nalbandian A, Sehgal K, Gupta A. Post-acute COVID-19 syndrome. Nat Med.
2021;27(4):601-15. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22. PMID: 33753937;
PMCID: PMC8893149.

11. Ramakrishnan RK, Kashour T, Hamid Q. Unraveling the Mystery Surrounding PostAcute Sequelae of COVID-19. Front Immunol. 2021;12 :686029. doi:
10.3389/fimmu.2021.686029. PMID: 34276671; PMCID: PMC8278217.

12. Crook H, Raza S, Nowell J. Long covid-mechanisms, risk factors, and management.
BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648. Erratum in: BMJ. 2021 Aug 3;374:n1944.
PMID: 34312178.

13. Ståhlberg M, Reistam U, Fedorowski A. Post-COVID-19 Tachycardia Syndrome: A
Distinct Phenotype of Post-Acute COVID-19 Syndrome. Am J Med. 2021;134(12):1451-6. doi:
10.1016/j.amjmed.2021.07.004. Epub 2021 Aug 11. PMID: 34390682; PMCID: PMC8356730.

Roe K. A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several
categories of COVID-19 patients. J Neurosci Res. 2021;99(10):2367-76. doi: 10.1002/jnr.24917.
Epub 2021 Jul 19. PMID: 34288064; PMCID: PMC8427009.

15. Kohno R, Cannom DS, Olshansky B. Mast Cell Activation Disorder and Postural
Orthostatic Tachycardia Syndrome: A Clinical Association. J Am Heart Assoc.
2021;10(17):e021002. doi: 10.1161/JAHA.121.021002. Epub 2021 Aug 16. PMID: 34398691;
PMCID: PMC8649306.

Mazzitelli I, Bleichmar L, Ludueña MG. Immunoglobulin G Immune Complexes May
Contribute to Neutrophil Activation in the Course of Severe Coronavirus Disease 2019. J Infect
Dis. 2021;224(4):575-85. doi: 10.1093/infdis/jiab174. PMID: 34398243; PMCID: PMC8083460.
Wang TT, Ravetch JV. Immune complexes: not just an innocent bystander in chronic

viral infection. Immunity. 2015;17(42):213-15. doi: 10.1016/j.immuni.2015.01.022. PMID:
25692698.

18. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated
intravascular coagulation. Int J Hematol. 2021;113(1):45-57. doi: 10.1007/s12185-020-03029-y.
Epub 2020 Nov 7. PMID: 33161508; PMCID: PMC7648664.

Mancini I, Baronciani L, Artoni A. The ADAMTS13-von Willebrand factor axis in
COVID-19 patients. J Thromb Haemost. 2021;19(2):513-21. doi: 10.1111/jth.15191. Epub 2020
Dec 18. PMID: 33230904; PMCID: PMC7753796.

Ward SE, Fogarty H, Karampini E. ADAMTS13 regulation of VWF multimer
distribution in severe COVID-19. J Thromb Haemost. 2021;19(8):1914-21. doi:
10.1111/jth.15409. Epub 2021 Jun 20. PMID: 34053187; PMCID: PMC8237059.

Oikonomou E, Souvaliotis N, Lampsas S. Endothelial dysfunction in acute and long
standing COVID-19: A prospective cohort study. Vascul Pharmacol. 2022;144:106975. doi:
10.1016/j.vph.2022.106975. Epub 2022 Mar 3. PMID: 35248780; PMCID: PMC8893931.

734 22. Farrell DH, Hudkins M, Hamiltonn H. Extreme gammaprime levels in COVID-19
735 patients. MedRxiv. 2022. https://doi.org/10.1101/2022.01.20.22269321.

Fogarty H, Townsend L, Morrin H. Persistent endotheliopathy in the pathogenesis of
long COVID syndrome. J Thromb Haemost. 2021;19(10):2546-53. doi: 10.1111/jth.15490. Epub
2021 Sep 12. PMID: 34375505; PMCID: PMC8420256.

- Macrae FL, Swieringa F, Heemskerk JWM. High fibrinogen gamma' levels in patient
 plasma increase clot formation at arterial and venous shear. Blood Adv. 2021;5(17):3468-77.
 doi: 10.1182/bloodadvances.2020003346. PMID: 34438442; PMCID: PMC8525222.
- 742 25. Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020;585:339-41.
 743 doi: 10.1038/d41586-020-02598-6. PMID: 32929257.

Heath C, Sommerfield A, von Ungern-Sternberg BS. Resilience strategies to manage
psychological distress among healthcare workers during the COVID-19 pandemic: A narrative
review. Anaesthesia. 2020;75:1634-371. doi: 10.1111/anae.15180. Epub 2020 Jul 3. PMID:
32534465; PMCID: PMC7323405.

Mazza C, Ricci E, Biondi S. Nationwide Survey of Psychological Distress among Italian
People during the COVID-19 Pandemic: Immediate Psychological Responses and Associated
Factors. Int J Environ Res Public Health. 2020;17:3165. doi: 10.3390/ijerph17093165. PMID:
32370116; PMCID: PMC7246819.

Giusti EM, Pedroli E, D'Aniello GE. The Psychological Impact of the COVID-19
Outbreak on Health Professionals: A Cross-Sectional Study. Front Psychol. 2020;11:1684. doi:
10.3389/fpsyg.2020.01684. PMID: 32754102; PMCID: PMC7366071.

Pandey D, Bansal S, Goyal S, Psychological impact of mass quarantine on population
during pandemics-The COVID-19 Lock-Down (COLD) study. PLoS ONE. 2020 Oct
22;15(10):e0240501. doi: 10.1371/journal.pone.0240501. PMID: 33091020; PMCID:
PMC7580982.

30. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5). American Psychiatric Association; 2013.

- 31. Orrù G, Bertelloni D, Diolaiuti F. Long-COVID Syndrome? A Study on the Persistence
 of Neurological, Psychological and Physiological Symptoms. Healthcare (Basel).
 2021;13(5):575. doi: 10.3390/healthcare9050575. PMID: 34068009; PMCID: PMC8152255.
- 32. Graham EL, Clark JR, Orban ZS. Persistent neurologic symptoms and cognitive
 dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol. 2021;
 8(5):1073-1085. doi: 10.1002/acn3.51350. Epub 2021 Mar 30. PMID: 33755344; PMCID:
 PMC8108421.
- 33. Singh H, Choudhari R, Nema V. ACE2 and TMPRSS2 polymorphisms in various
 diseases with special reference to its impact on COVID-19 disease. Microb Pathog
 2021;150:104621. doi: 10.1016/j.micpath.2020.104621. Epub 2020 Dec 2. PMID: 33278516;
 PMCID: PMC7709597.
- 34. Glotov OS, Chernov AN, Scherbak SG. Genetic Risk Factors for the Development of
 COVID-19 Coronavirus Infection. Russ J Genet. 2021;57:878-92. doi:
 10.1134/S1022795421080056. Epub 2021 Aug 30. PMID: 34483599; PMCID: PMC8404752.
- 35. Srivastava A, Bandopadhyay A, Das D. Genetic association of ACE2 rs2285666
 polymorphism with COVID-19 spatial distribution in India. Front Genet 2020; 11:564741. doi:
 10.3389/fgene.2020.564741. PMID: 33101387; PMCID: PMC7545580.
- Ravikanth V, Sasikala M, Naveen V, A variant in TMPRSS2 is associated with
 decreased disease severity in COVID-19. Meta Gene 2021;25 :100930. doi:
 10.1016/j.mgene.2021.100930. Epub 2021 May 28. PMID: 34075330; PMCID: PMC8161869.
- 781 37. Dobrijevic Z, Robajac D, Gligorijevic N. The association of ACE1, ACE2, TMPRSS2,

782 IFITM3 and VDR polymorphisms with COVID-19 severity: A systematic review and meta-

analysis. EXCLI J. 2022;21:819-39. doi: 10.17179/excli2022-4976. PMID: 35949487; PMCID:
PMC9360474.

38. Gupta K, Kaur G, Pathak T. Systematic review and meta-analysis of human genetic
variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844 :146790. doi:
10.1016/j.gene.2022.146790. Epub 2022 Aug 17. PMID: 35987511; PMCID: PMC9384365.

Martínez-Gómez LE, Herrera-López B, Martinez-Armenta C. ACE and ACE2 gene
variants are associated with severe outcomes of COVID-19 in men. Immunol. 2022;13 :812940.
doi: 10.3389/fimmu.2022.812940. PMID: 35250987; PMCID: PMC8892378.

40. Wulandari L, Hamidah B, Pakpahan C. Initial study on TMPRSS2 p. Val160Met genetic
variant in COVID-19 patients. Hum Genom. 2021; 15(1):29. doi: 10.1186/s40246-021-00330-7.
PMID: 34001248; PMCID: PMC8127183..

41. Saengsiwaritt W, Jittikoon J, Chaikledkaew U. polymorphisms of ACE1, ACE2, and
TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis. Rev
Med Virol. 2022;32(4):e2323. doi: 10.1002/rmv.2323. Epub 2022 Jan 8. PMID: 34997794.

Ni W, Yang X, Yang D. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
Crit Care 2020; 24(1):422. doi: 10.1186/s13054-020-03120-0. PMID: 32660650; PMCID:

799 PMC7356137.

43. Gheblawi M, Wang K, Viveiros A. Angiotensin-Converting Enzyme 2: SARS-CoV-2
receptor and regulator of the renin-angiotensin system. Circ Res 2020; 126(10):1456-1474. doi:
10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8. PMID: 32264791; PMCID:
PMC7188049..

44. Castanares-Zapatero D, Chalon P, Kohn L. Pathophysiology and Mechanism of Long
COVID: A Comprehensive Review. Ann Med 2022; 54(1):1473-1487. doi:
10.1080/07853890.2022.2076901. PMID: 35594336; PMCID: PMC9132392.

PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation
profiling of long COVID and association with 1-year recovery following hospitalisation in the
UK: A prospective observational study. Lancet Respir Med 2022; 10(8):761-775. doi:
10.1016/S2213-2600(22)00127-8. Epub 2022 Apr 23. Erratum in: Lancet Respir Med. 2022 Jul
26:: PMID: 35472304; PMCID: PMC9034855.

46. Fernández-de-Las-Peñas C, Arendt-Nielsen L, Díaz-Gil G. Genetic Association between
ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms
with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors Genes (Basel).
2022;13(11):1935. doi: 10.3390/genes13111935. PMID: 36360172; PMCID: PMC9690177.

47. Fernández-de-Las-Peñas C, Arendt-Nielsen L, Díaz-Gil G. ACE1 rs1799752
polymorphism is not associated with long-COVID symptomatology in previously hospitalized
COVID-19 survivors. J Infect. 2023;86(3):e67-e69. doi: 10.1016/j.jinf.2022.12.026. Epub 2022
Dec 28. PMID: 36584771; PMCID: PMC9794395.

48. Fu Q, Vangundy TB, Shibata S. Exercise training versus propranolol in the treatment of
the postural orthostatic tachycardia syndrome. Hypertension. Hypertension. 2011;58(2):167-75.
doi: 10.1161/HYPERTENSIONAHA.111.172262. Epub 2011 Jun 20. PMID: 21690484;
PMCID: PMC3142863.

49. Raj SR, Guzman JC, Harvey P. Canadian cardiovascular society position statement on
postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic
intolerance. Canadian Journal of Cardiology. 2020;36(3):357-72. doi:
10.1016/j.cjca.2019.12.024. PMID: 32145864.

50. Taub PR, Zadourian A, Lo HC, Ormiston CK. Randomized Trial of Ivabradine in
Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol
2021;77:861-71. doi: 10.1016/j.jacc.2020.12.029. PMID: 33602468.

831 51. M Maruish, M Kosinski, J Bjorner. User's manual for the SF-36v2 health survey (3rd
832 ed.). Lincoln, RI: QualityMetric Incorporated. 2011.

52. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire Somatic,
Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry.
2010;32:345-9.

836 53. Henry JD. The short \Box form version of the Depression Anxiety Stress Scales (DASS \Box 21):

Construct validity and normative data in a large non □ clinical sample. British journal of clinical
psychology. 2005;44(2):227-39. doi: 10.1016/j.genhosppsych.2010.03.006. Epub 2010 May 7.
PMID: 20633738.

54. Iverson GL, Marsh JM, Connors EJ. Normative reference values, reliability, and itemlevel symptom endorsement for the PROMIS® v2. 0 cognitive function-short forms 4a, 6a and
8a. Archives of clinical neuropsychology. 2021;36(7):1341-9. doi: 10.1093/arclin/acaa128.
PMID: 33454756.

55. First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-

5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA,

846 American Psychiatric Association; 2015.

56. Heaton RK, Akshoomoff N, Tulsky D. Reliability and validity of composite scores from
the NIH Toolbox Cognition Battery in adults. Journal of the International Neuropsychological
Society. 2014;20(6):588-98. doi: 10.1017/S1355617714000241. Epub 2014 Jun 24. PMID:

850 24960398; PMCID: PMC4103963.

- 57. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other
 autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunologic
 research. 2021;69(2):205-11. doi: 10.1007/s12026-021-09185-5. Epub 2021 Mar 30. Erratum in:
 Immunol Res. 2021 Apr 13;: PMID: 33786700; PMCID: PMC8009458
- S8. Carmona-Torre F, Mínguez-Olaondo A, López-Bravo A. Dysautonomia in COVID-19
 patients: a narrative review on clinical course, diagnostic and therapeutic strategies. Front
 Neurol. 2022;13:886609. doi: 10.3389/fneur.2022.886609. PMID: 35720084; PMCID:
 PMC9198643.
- 859 59. Rangon CM, Krantic S, Moyse E. The vagal autonomic pathway of COVID-19 at the
 860 crossroad of Alzheimer's disease and aging: a review of knowledge. Journal of Alzheimer's
 861 Disease Reports. 2020;4(1):537-51. doi: 10.3233/ADR-200273. PMID: 33532701; PMCID:
 862 PMC7835993.
- 863 60. Eisenkraft A, Maor Y, Constantini K. Trajectories of key physiological parameters in
 864 COVID-19 patients using continuous remote monitoring and health AI.
 865 https://assets.researchsquare.com/files/rs-122775/v1/f62a1fd0-c0cf-4fba-829b-
- 866 <u>f45d7f10a1e1.pdf?c=1631867089</u>. Accessed 23 March 2023.
- 867 61. Sandroni P, Opfer-Gehrking TL, McPhee BR. Postural tachycardia syndrome: clinical
 868 features and follow-up study. Mayo Clinic Proceedings 1999;74(11):1106-10. doi:
 869 10.4065/74.11.1106. PMID: 10560597.
- 870
- 871

Tables and figures - Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized Controlled Trial of Ivabradine for those with Postural Orthostatic Tachycardia Syndrome (The COVIVA Study).

Table 1. COVIVA Study Objectives.

#	Objective	Study Endpoints/Milestones
1.	To assess the frequency and severity of fatigue, dyspnea, headache, and confusion and other suggestive symptoms among volunteers with and without LHC and measure the occurrence of clinically confirmed POTS or IST—in relation to these symptoms	Proportions of LHC and non-LHC volunteers with postural orthostatic tachycardia syndrome (POTS), and disease severity based on a composite of physiologic (ambulatory EKG, vital signs, orthostatics, see Objective 3) and well-being assessments (see Objective 5).
2.	To assess whether treatment with ivabradine will significantly reduce heart rate and improve symptoms and quality of life among subjects manifesting typical POTS or similar autonomic dysregulation	The primary endpoint of the nested ivabradine RCT will be a reduction in standing heart rate at three months. Based on a prior small cross-over RCT in POTS patients without a history of COVID-19, a reduction of roughly 16 bpm in standing heart rate between the treated and placebo groups was observed. ¹
3.	To determine whether wearable automated ambulatory monitoring with existing FDA-approved devices will permit improved diagnostic accuracy for POTS.	The differential proportion of individuals diagnosed with POTS using conventional (in-office) and wearable diagnostic methods.
4.	To determine the degree to which LHC induces autonomic instability and whether it is associated with induced inflammation and/or dysregulation	Degree and severity of POTS as in Objectives 1 and 3. Levels of circulating catecholamines measured in the blood before and after orthostatic maneuvers.
5.	To evaluate potential contribution of psychological symptoms and the interplay between psychosocial symptoms, quality of life, cognitive symptoms, and physiologic responses induced by LHC.	Improvements/changes in quality of life measured by the SF-36, psychosocial functioning measured by the PHQ-SADS and DASS-21 surveys, and cognitive function measured by the PROMIS cognition survey and NIH Toolbox tasks.
6.	To determine whether LHC improves following vaccination (in the limited number of cases where late vaccination occurs) and/or "breakthrough" clinical COVID-19 infection.	Changes in longitudinal quality of life and symptoms surveys and/or laboratory markers of infection in those receiving vaccination or contracting infection during the study.
7.	Assess whether individuals with LHC have different antibody and/or cellular immune responses to SARS-CoV-2 antigens compared to infected individuals who did not develop LHC	 Assess whether IgG antibodies to SARS-CoV-2 or the four major seasonal human coronaviruses (HCoV- OC43, HCoV-HKU1, HCoV-229E, or HCoV- NL63) are associated with LHC. Assess if T-cell cytokine responses against SARS- CoV-2 proteins are associated with LHC. Evaluate whether individuals with LHC have decreased immunoregulatory networks compared to infected individuals who did not develop LHC. Assess NK cell phenotypic/functional differences in LHC and non-LHC volunteers. Identify if orthostasis in POTS disease is associated with release of mast cell degranulation and basophil activation products such as histamine and tryptase, and evaluate whether basophil responsiveness to activation in response to mediators released by parasympathetic nerves such as Calcitonin gene-related peptide (CGRP) and Substance P is different between individuals with

		POTS disease and those without.
8.	Assess whether specific plasma protein markers of dysregulated blood coagulation, which were significantly correlated with immunothrombosis in severe COVID-19, persist in individuals with LHC	Clinical or research-grade laboratory assays will quantify and characterize specific markers of dysregulated coagulation and immunothrombosis. Assays will include PT, APTT, factor VIII:C, total fibrinogen, D-dimer, thrombin generation assay and thromboelastometry (ROTEM) assay. Additional analytes may include gammaprime fibrinogen, von Willebrand factor (VWF) antigen, VWF propeptide, ADAMTS13 activity and soluble thrombomodulin.

Figure 1. Overall Study Schema



Figure 2. COVIVA Study Schedule of Events



16. Concomitant Medications



- 3. Dose Adjustments
- 4. Drug Levels

7. Month 3

8. Month 6

Orthostatic Vital Signs

Covid 19 immunology

1.

2.

3.

4.

5.

6.

7.

8.

testing

(PBMC)

Interval H&P

Multi-omic assays

Hematology assays

Psychosocial, Quality of

Life, and Cognitive Surveys

Adverse events

EKG

9. Year 1

- **Orthostatic Vital Signs** 1.
- 2. Covid 19 immunology testing
- 3. EKG
- 4. Interval H&P
- 5. PFTs/Dyspnea-12
- Multi-omic assays (PBMC) 6.
- 7. Safety labs
- 8. Immunologic assays
- 9. **Basophil activation**
- 10. Hematology assays
- 11. Adverse events
- Ambulatory EKG 12.
- Ambulatory vital signs 13.
- 14. Cardiac symptom diary
- 15. Structured clinical interview 16. Psychosocial, Quality of Life,
- and Cognitive SurveysCognitive performance tasks 17. Metabolic Testing
- 18. Concomitant Medications

RCT TRIAL

- **Enroll to RCT/Randomize** 1.
- 2. Drug Levels/Dose Adjustements
- 3. Unblided DSMB Assessment
- 4. PK/PD Assessment

9.	Cognitive performance
	tasks
10.	Metabolic Testing
11.	Concomitant Medications

RCT TRIAL

- **Dose Adjustments** 1.
- 2. Drug Levels

1.	Orthostatic Vital Signs
2.	Covid 19 immunology testing
3.	EKG
4.	Interval H&P
5.	PFTs/Dyspnea-12
6.	Multi-omic assays (PBMC)
7.	Safety labs
8.	Basophil activation
9.	Adverse events
10.	Ambulatory EKG
11.	Ambulatory vital signs
12.	Cardiac symptom diary
13.	Psychosocial, Quality of Life,
	and Cognitive Surveys
14.	Cognitive performance tasks
15.	Metabolic Testing
16.	Concomitant Medications

- **Dose Adjustments** 1.
- Drug Levels 2.
- Echocardiogram 3.

Figure 3. COVIVA Study SPIRIT Figure

	STUDY PERIOD								
	Cohort screen (Up to day 60)	Cohort screen (Up to day 60)	Enroll RCT		Post-allocation				
TIMEPOINT**	-t ₂	-t ₁	0	Week 1 t ₁	Week 2 t ₂	Month 1 t ₃	Month 3 t ₄	Month 6 t₅	Year 1 t ₆
ASSESSMENTS				_		_	_		
Informed Consent	Х								
Orthostatic vital signs	Х	х	Х	(X)	(X)	Х	Х	Х	Х
History & physical exam	Х								
COVID-19 history	Х								
Electrocardiogram (EKG)	Х	х	Х	(X)	(X)	Х	х	Х	Х
Pulmonary Function Test /Dyspnea-12 Score	Х						х		Х
Structured clinical interview (DSM-5)	Х			(X)			Х		
Psychosocial, quality of life and cognitive surveys	Х	х				Х	х	Х	Х
Concomitant medications	Х	х	Х	(X)	(X)	Х	Х	Х	Х
COVID-19 Immunity testing		х					х	Х	Х
Enroll to Observational Cohort		х							
Interval history/physical		Х	Х	(X)	(X)	Х	Х	Х	Х

Multi-omic assays		X		(X)	(X)	X	Х		Х
Genomic analysis		Х							
Immunologic assays		Х					Х		
Hematology assays		Х		(X)			Х	Х	
Ambulatory EKG		Х	Review		(X)	Review	Х		Х
Ambulatory vital signs		Х	Review		(X)	Review	Х		Х
Cardiac symptom diary		Х	Review		(X)	Review	Х		Х
Cognitive performance tasks		Х						Х	Х
Metabolic testing		Х	(X)			(X)	(X)	(X)	х
Safety labs			(X)			X	Х		х
Basophil activation*			(X)			X	Х		х
Adverse events			(X)	(X)	(X)	(X)	(X)	(X)	(X)
For Ivabradine RCT particip	oants only								
Enroll to RCT/Randomize			Х	Х			Х		
Ivabradine or placebo treatment***			10000000000000						
Echocardiogram			Х						Х
Dose Adjustments				Х	х	Х	Х	Х	Х
Unblinded DSMB assessment							Х		
Rich PK/PD assessment							X**		

Ivabradine Levels		Х	Х	Х	Х	Х	Х	Х
-------------------	--	---	---	---	---	---	---	---

(X) – performed only for those enrolled in the RCT

- * Performed only for a subset of individuals
- ** Performed only for those individuals randomized to placebo

*** - All volunteers in the RCT will receive ivabradine following the Data Safety Monitoring Board assessment at month 3